These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37377931)

  • 21. Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension.
    Murata M; Kawakami T; Kataoka M; Moriyama H; Hiraide T; Kimura M; Endo J; Kohno T; Itabashi Y; Fukuda K
    Cardiology; 2021; 146(1):130-136. PubMed ID: 33238268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
    Burudpakdee C; Shah A; Joish VN; Divers C; Yaldo A
    Am Health Drug Benefits; 2014 Dec; 7(9):479-87. PubMed ID: 25610527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies.
    Thenappan T; Al-Naamani N; Ghio S; Ghofrani HA; Hassoun PM; Pritzker M; Torbicki A; Nikkho S; Busse D; Preston IR
    Pulm Circ; 2020; 10(4):2045894020963836. PubMed ID: 33282192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Benza RL; Langleben D; Hemnes AR; Vonk Noordegraaf A; Rosenkranz S; Thenappan T; Hassoun PM; Preston IR; Ghio S; Badagliacca R; Vizza CD; Lang IM; Meier C; Grünig E
    Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36198418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
    Jaïs X; Brenot P; Bouvaist H; Jevnikar M; Canuet M; Chabanne C; Chaouat A; Cottin V; De Groote P; Favrolt N; Horeau-Langlard D; Magro P; Savale L; Prévot G; Renard S; Sitbon O; Parent F; Trésorier R; Tromeur C; Piedvache C; Grimaldi L; Fadel E; Montani D; Humbert M; Simonneau G
    Lancet Respir Med; 2022 Oct; 10(10):961-971. PubMed ID: 35926542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Connexin 43 plays a role in proliferation and migration of pulmonary arterial fibroblasts in response to hypoxia.
    McNair AJ; Wilson KS; Martin PE; Welsh DJ; Dempsie Y
    Pulm Circ; 2020; 10(3):2045894020937134. PubMed ID: 32670564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corrigendum for
    Pulm Circ; 2021; 11(2):20458940211007752. PubMed ID: 33854769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT.
    van der Have O; Westöö C; Ahrné F; Tian X; Ichimura K; Dreier T; Norvik C; Kumar ME; Spiekerkoetter E; Tran-Lundmark K
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 35332070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis.
    Herrmann FE; Hesslinger C; Wollin L; Nickolaus P
    Front Pharmacol; 2023; 14():1219760. PubMed ID: 37324497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
    Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension.
    Sahay S; Rahaghi F
    Pulm Circ; 2020; 10(1):2045894020910098. PubMed ID: 32166019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP
    Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
    Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.
    Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M
    Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.
    Domingo LT; Ivy DD; Abman SH; Grenolds AM; MacLean JT; Breaux JA; Minford KJ; Frank BS
    Front Pediatr; 2022; 10():1014922. PubMed ID: 36533232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corrigendum: Integrated metabolomics and proteomics reveal biomarkers associated with hemodialysis in end-stage kidney disease.
    Lin W; Mousavi F; Blum BC; Heckendorf CF; Moore J; Lampl N; McComb M; Kotelnikov S; Yin W; Rabhi N; Layne MD; Kozakov D; Chitalia VC; Emili A
    Front Pharmacol; 2024; 15():1376058. PubMed ID: 38405670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
    Saleh S; Becker C; Frey R; Mück W
    Pulm Circ; 2016 Mar; 6(Suppl 1):S86-96. PubMed ID: 27162632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.